Efficacy of Agomelatine in Generalized Anxiety Disorder

Dan Joseph Stein; Antti Ahokas; Christian de Bodinat

doi:10.1097/jcp.0b013e318184ff5b

Abstract

1 min read

This study suggests that agomelatine is effective in the treatment of GAD and is well tolerated. Additional trials, using an active comparator and extending over a longer period, are needed to delineate the place of agomelatine in the contemporary pharmacotherapy for anxiety disorders.

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article2011

SS05-04 - Overcoming the challenges of the anxiety spectrum

Dan Joseph Stein

Article2017

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study

Dan Joseph Stein, Antti Ahokas, Marek Jarema, А С Аведисова, L. Vavrušová, Олег Чабан, C. Gruget, Valérie Olivier, F. Picarel-Blanchot, Christian de Bodinat

Article2023

Evidence-Based Pharmacotherapy of Anxiety Symptoms in Patients with Major Depressive Disorder: Focus on Agomelatine

Dan Joseph Stein

Article2021

Evidence-Based Pharmacotherapy of Generalised Anxiety Disorder: Focus on Agomelatine

Dan Joseph Stein

Article2009

The DSM-IV-Based Generalized Anxiety Disorder Severity Scale

Dan Joseph Stein, Dylan Fincham, Soraya Seedat, Christian de Bodinat, Antti Ahokas